TOP2B
DNA topoisomerase 2-beta
As of the edition of 20 October 2026, TOP2B (DNA topoisomerase 2-beta, UniProt Q02880) has 9 drugs tested at it and 17 companies on the list, 4 on route A and 6 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q02880
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 21
- Disease areas
- Cancer; Blood and lymph; Immune system; Lungs and airways; Infections; Urinary and reproductive; Nervous system; Heart and blood vessels
- Registered trials of its drugs
- 1,373
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 5 |
| Active | 1 |
| Stopped | 3 |
| Total | 9 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Etoposide | Marketed | Phase 4 | none listed |
| Dexrazoxane | Marketed | Phase 3 | none listed |
| Teniposide | Marketed | Phase 4 | none listed |
| Aclarubicin | Active | Phase 3 | none listed |
| Vosaroxin | Stopped | Phase 3 | none listed |
| Becatecarin | Stopped | Phase 3 | none listed |
| Amsacrine | Marketed | Phase 4 | none listed |
| Berubicin | Stopped | Phase 2 | none listed |
| Pazufloxacin | Marketed | Phase 3 | none listed |
9 of 9 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Route B | 6 |
| Engaged | 4 |
| Undetermined | 3 |
| Total on the list | 17 |
| Company | Route |
|---|---|
| Pfizer | Route B |
| Hq Specialty Pharma | Route B |
| CNX Therapeutics | Route B |
The other 14 companies at TOP2B
In the product17 companies in all; 14 are not named here, and no score is.
See the 17 companies at TOP2B, ranked, with the facts behind eachRequest access. Nothing is shown until you do.